Treatment with inhaled fluticasone furoate for 14 days did not result in a shorter time to recovery in outpatients with COVID-19 in the United States.
This double-blind, randomized, placebo-controlled platform study assessed the use of repurposed medications in outpatients with COVID-19. Adult patients aged 30 years or older who had at least 2 symptoms of acute infection present for no more than 7 days before enrollment were randomized to inhaled fluticasone furoate at a dose of 200 µg once daily for 14 days or placebo. The primary outcome measure was time to recovery, defined as 3 consecutive days without symptoms. The main secondary outcome was hospitalization or death within 28 days.
Of the 1407 included participants who underwent randomization, 715 were assigned to inhaled fluticasone furoate and 692 to placebo. Of these, 656 and 621 were included in the analysis, respectively. There was no evidence that the use of fluticasone furoate resulted in a shorter time to recovery compared to placebo (HR 1.01; 95% credible interval 0.91-1.12; posterior probability of benefit (HR > 1): 0. 56). A total of 24 participants (3.7%) in the fluticasone furoate group had an emergency department visit or hospitalization, compared to 13 participants (2.1%) in the placebo group (HR 1.9; 95% credible interval 0.8-3.5). In both groups, 3 participants were hospitalized and none of the participants died. The incidence of adverse events was similar between groups: 2.0% with fluticasone furoate versus 2.5% in the placebo group.
2024-01-10 10:06:20
#Inhaled #corticosteroids #outpatient #treatment #COVID19 #MedNet
